- Email: [email protected]
Poster Session 35
Tuesday, May 7, 1996
Podium Session 35
3:30 pm to 5:20 pm
REVELATIONS IN TREATMENT OF BPH
Valencia B Room, Orange County Convention Center Moderators: Michael L. Blute, Rochester, MN John D. McConnell, Dallas, TX (Note: all presentations are 9 minutes in length.)
3:30
#1099
Long-term evaluation of tamsulosin, a prostate selective alpha 1 antagonist. Herbert Lepor, New York, NY and the Tamsulosin Investigator Group (Presented by Dr. Lepor).
3:40
#1100
Clinical correlation of maximum flow rate and plasma doxazosin levels in treatment of benign prostatic hyperplasia (BPH). Jerry W. Sullivan and Ahmed Fawzy, New Orleans, LA; V. Vashi, M. Chung, N. Dias and M. Gaffney, New York, NY (Presented by Dr. Sullivan).
3:50
4:00
#1101
#1102
"The Wedge": a new resection loop for transurethral prostatectomy. Aaron P. Perlmutter, New York, NY (Presented by Dr. Perlmutter).
4:20
#1103
#1104
#1105
A department of veterans affairs (VA) cooperative randomized placebo controlled clinical trial of the safety and efficacy of terazosin and finasteride monotherapy and terazosin/finasteride combination therapy in men with clinical BPH. Herbert Lepor for the VA Cooperative Studies BPH Study Group, New York, NY (Presented by Dr. Lepor).
4:40
#1106
Alpha blockade down regulates smooth muscle heavy chain gene expression in human BPH. Victor K. Lin, Elie Benaim, Hossein Soboorian and John D. McConnell, Dallas, TX (Presented by Dr. Lin).
4:50
#1107
Management decisions for BPH: an investigation of urologist's practice patterns. J.E. Mahoney, D. Fish and A. Grenville, Toronto, Canada (Presented by Dr. Mahoney).
5:00
#1108
The affinity of a new prostate selective cd - adreno-
The natural history of benign prostatic hypertro-
phy: incidence of urinary retention and significance of AUA symptom score. William J. Somers, Columbus, OH; Miguel J. Mora, Michael F. Mason and Robert J. Padley for the HYCAT Investigator Group, Waukegan, IL (Presented by Dr. Somers). 4:10
4:30
ceptor antagonist at functional c~l-adrenoceptors. Amanda J. Noble, Russell Chess-Williams, Caroline J. Couldwell and Christopher R. Chapple, Sheffield, UK (Presented by Dr. Chess-Williams).
Subjective assessmentsof changes in symptom frequency, bother, and quality of life in men with BPH depend on baseline variables and treatment modality. Robert J. Padley, Waukegan, IL; Claus G. Roehrborn, Dallas, TX; Joseph E. Oesterling, Ann Arbor, MI; Michael J. Barry,for the HYCAT Investigator Group, Boston, MA (Presented by Dr. Roehrborn).
5:10
Five-year follow-up of transurethral microwave thermotherapy versus transurethral resection for benign prostatic obstruction. Christer Dahlstrand and Silas Pettersson, G6teborg, Sweden (Presented by Dr. Dahlstrand).
186
#1109
A comparison of short-term effects of transurethral resection, laser procedures, and electro-vaporization of the prostate. Erik G. Enquist, Michael Granovsky, Harry C. Miller and Michael J. Manyak, Washington, DC (Presented by Dr. Enquist).
Podium Session 35
3:30 pm to 5:20 pm
REVELATIONS IN TREATMENT OF BPH
Valencia B Room, Orange County Convention Center Moderators: Michael L. Blute, Rochester, MN John D. McConnell, Dallas, TX (Note: all presentations are 9 minutes in length.)
3:30
#1099
Long-term evaluation of tamsulosin, a prostate selective alpha 1 antagonist. Herbert Lepor, New York, NY and the Tamsulosin Investigator Group (Presented by Dr. Lepor).
3:40
#1100
Clinical correlation of maximum flow rate and plasma doxazosin levels in treatment of benign prostatic hyperplasia (BPH). Jerry W. Sullivan and Ahmed Fawzy, New Orleans, LA; V. Vashi, M. Chung, N. Dias and M. Gaffney, New York, NY (Presented by Dr. Sullivan).
3:50
4:00
#1101
#1102
"The Wedge": a new resection loop for transurethral prostatectomy. Aaron P. Perlmutter, New York, NY (Presented by Dr. Perlmutter).
4:20
#1103
#1104
#1105
A department of veterans affairs (VA) cooperative randomized placebo controlled clinical trial of the safety and efficacy of terazosin and finasteride monotherapy and terazosin/finasteride combination therapy in men with clinical BPH. Herbert Lepor for the VA Cooperative Studies BPH Study Group, New York, NY (Presented by Dr. Lepor).
4:40
#1106
Alpha blockade down regulates smooth muscle heavy chain gene expression in human BPH. Victor K. Lin, Elie Benaim, Hossein Soboorian and John D. McConnell, Dallas, TX (Presented by Dr. Lin).
4:50
#1107
Management decisions for BPH: an investigation of urologist's practice patterns. J.E. Mahoney, D. Fish and A. Grenville, Toronto, Canada (Presented by Dr. Mahoney).
5:00
#1108
The affinity of a new prostate selective cd - adreno-
The natural history of benign prostatic hypertro-
phy: incidence of urinary retention and significance of AUA symptom score. William J. Somers, Columbus, OH; Miguel J. Mora, Michael F. Mason and Robert J. Padley for the HYCAT Investigator Group, Waukegan, IL (Presented by Dr. Somers). 4:10
4:30
ceptor antagonist at functional c~l-adrenoceptors. Amanda J. Noble, Russell Chess-Williams, Caroline J. Couldwell and Christopher R. Chapple, Sheffield, UK (Presented by Dr. Chess-Williams).
Subjective assessmentsof changes in symptom frequency, bother, and quality of life in men with BPH depend on baseline variables and treatment modality. Robert J. Padley, Waukegan, IL; Claus G. Roehrborn, Dallas, TX; Joseph E. Oesterling, Ann Arbor, MI; Michael J. Barry,for the HYCAT Investigator Group, Boston, MA (Presented by Dr. Roehrborn).
5:10
Five-year follow-up of transurethral microwave thermotherapy versus transurethral resection for benign prostatic obstruction. Christer Dahlstrand and Silas Pettersson, G6teborg, Sweden (Presented by Dr. Dahlstrand).
186
#1109
A comparison of short-term effects of transurethral resection, laser procedures, and electro-vaporization of the prostate. Erik G. Enquist, Michael Granovsky, Harry C. Miller and Michael J. Manyak, Washington, DC (Presented by Dr. Enquist).